| Document Date: 2013-08-06 15:12:49
Open Document File Size: 143,37 KBShare Result on Facebook
City Osaka / Newton / Napa / Tampere / Suzhou / / Company CombinatoRx Inc. / Novartis / Osaka Stock Exchange / Santen Pharmaceutical Co. Ltd. / Clinical Data Inc. / Santen Inc. / Santen OY / A2A / Santen Pharmaceutical (China) Co. Ltd. / Takashi Hibi Corporate Communication Group Santen Pharmaceutical Co. Ltd. / / Continent Asia / Europe / / Country Japan / United States / China / Finland / / Currency USD / / Event FDA Phase / Business Partnership / / Facility Clinical Data’s library / National Eye Institute / / IndustryTerm biotechnology / medical insurance / or acquire additional products / cancer therapies / treatment for any ophthalmic disease / pharmaceutical / ophthalmic products / prescription ophthalmic pharmaceuticals / pharmaceuticals / myocardial perfusion imaging / / MedicalCondition glaucoma / Inc. for developing B-cell cancer / certain ophthalmic diseases / B-cell cancers / Glaucoma Glaucoma / disorder / ophthalmic diseases / cardiovascular diseases / II diabetes / blindness / asthma / pain disorders / pain / ophthalmic disease / inflammatory conditions / open-angle glaucoma / certain eye disorders / central nervous system disorders / inflammatory / / MedicalTreatment cancer therapies / / Organization National Eye Institute / World Health Organization / U.S. Securities and Exchange Commission / U.S. Food and Drug Administration / / Person Akira Kurokawa / Drew Fromkin / / / Position Theresa McNeely Vice President Corporate Communications / President and CEO / Private / / Product ATL313 / Adenosine / Stedivaze / / ProvinceOrState Indiana / California / Massachusetts / / Technology biotechnology / pharmacokinetics / ophthalmic products / drug development / ophthalmic / / URL www.santen.com / http /
SocialTag |
One Gateway Center, Suite 702, Newton, MA[removed]USA NEWS FOR IMMEDIATE RELEASE Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for